Moxifloxacin Hydrochloride (Page 2 of 12)

1.7 Acute Bacterial Exacerbation of Chronic Bronchitis

Moxifloxacin Tablets are indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis [see Clinical Studies (14.2)].

Because fluoroquinolones, including Moxifloxacin Tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve Moxifloxacin Tablets for treatment of ABECB in patients who have no alternative treatment options.

1.8 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Tablets and other antibacterial drugs, Moxifloxacin Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adult Patients

The dose of Moxifloxacin Tablets is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.

Table 1: Dosage and Duration of Therapy in Adult Patients
Type of Infection * Dose Every 24 hours Duration (days)
*
Due to the designated pathogens [see Indications and Usage ( 1)] .
Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician
Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.
Community Acquired Pneumonia ( 1.1) 400 mg 7–14
Uncomplicated Skin and Skin Structure Infections (SSSI ) ( 1.2) 400 mg 7
Complicated SSSI ( 1.3) 400 mg 7–21
Complicated Intra-Abdominal Infections ( 1.4) 400 mg 5–14
Plague ( 1.5) 400 mg 10–14
Acute Bacterial Sinusitis (ABS) ( 1.6) 400 mg 10
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) ( 1.7) 400 mg 5

Conversion of Intravenous to Oral Dosing in Adults

Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with moxifloxacin injection may be switched to Moxifloxacin Tablets when clinically indicated at the discretion of the physician.

2.2 Important Administration Instructions

Moxifloxacin Tablets

With Multivalent Cations

Administer Moxifloxacin Tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

With Food

Moxifloxacin Tablets can be taken with or without food, drink fluids liberally.

Missed DosesIf a dose is missed, it should be taken anytime but not later than 8 hours prior to the next scheduled dose. If less than 8 hours remain before the next dose, the missed dose should not be taken and treatment should be continued as prescribed with the next scheduled dose. Double doses should not be taken to compensate for a missed dose.

3 DOSAGE FORMS AND STRENGTHS

3.1 Moxifloxacin Tablets USP

Pale red, capsule-shaped, film-coated tablets imprinted with “400” on one side containing 400 mg moxifloxacin.

4 CONTRAINDICATIONS

Moxifloxacin Tablets are contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials [see Warnings and Precautions (5.8)] .

5 WARNINGS AND PRECAUTIONS

5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects

Fluoroquinolones, including Moxifloxacin Tablets, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting Moxifloxacin Tablets. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.4)] .

Discontinue Moxifloxacin Tablets immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including Moxifloxacin Tablets, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.